Product name: Exenatide Acetate
CAS: 141732-76-5
Molecular formula:C184H282N50O60S.C2H4O2
Molecular weight:4262.67
Description:
Mechanism
Incretin as glucagon-like peptide -1 (GLP-1), is released into the circulation from the intestine can be enhanced glucose-dependent insulin secretion, and display other antihyperglycemic effect. Exenatide is an incretin intended drug can simulate enhanced glucose-dependent insulin secretion and action of incretin other antihyperglycemic effect.
The amino acid sequence of exendin and GLP-1 human overlap. Exenatide can bind in vitro display and activate the known human GLP-1 receptor. This means that by including cAMP and / or other intracellular signal transduction mechanism of insulin synthesis and glucose-dependent increase in pancreatic beta cell insulin secreted by the body. In the case of glucose concentration, exenatide may promote insulin release from beta cells. Vivo administration that a GLP-1 peptide analog antihyperglycemic effect.
Exenatide injection in patients with type 2 diabetes to reduce fasting and postprandial glucose concentrations, the following action to improve glycemic control.